OCTREOTIDE ACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCTREOTIDE ACETATE (OCTREOTIDE ACETATE).
Synthetic octapeptide analog of somatostatin with greater potency. Binds to somatostatin receptors (SSTR2 and SSTR5), inhibiting growth hormone, glucagon, insulin, and gastrointestinal peptide secretion. Also reduces splanchnic blood flow and suppresses tumor growth in neuroendocrine tumors.
| Metabolism | Primarily hepatic metabolism by CYP3A4; also metabolized by peptidases. Approximately 32% excreted unchanged in urine. |
| Excretion | Approximately 32% excreted unchanged in urine; the remainder is cleared via biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is 1.7–1.9 hours (subcutaneous) and 1.5–2.0 hours (intravenous). For long-acting release (LAR) formulation, apparent half-life is longer due to slow release. |
| Protein binding | 65% bound to plasma proteins, primarily to alpha-1-acid glycoprotein and albumin. |
| Volume of Distribution | 0.2–0.4 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous: 100% (absolute); Intramuscular LAR: 25–30% (relative to subcutaneous due to slow release). |
| Onset of Action | Subcutaneous: 30 minutes; Intravenous: immediate; Intramuscular (LAR): 2 weeks for therapeutic effect. |
| Duration of Action | Subcutaneous: 8–12 hours; Intravenous: 8–12 hours; Intramuscular (LAR): 28 days. |
| Molecular Weight | 1019.34 |
Initial: 50 mcg subcutaneously 2-3 times daily; titrate to 100-200 mcg 2-3 times daily. For acromegaly: 50 mcg subcutaneously 3 times daily, increase to 100-500 mcg 3 times daily. For carcinoid tumors: 100-600 mcg subcutaneously 2-4 times daily. Intravenous infusion: 25-50 mcg/hr continuous IV.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl <30 mL/min: No dose adjustment recommended in labeling; however, monitor closely due to potential accumulation. No specific guidelines for CrCl 30-50 mL/min. |
| Liver impairment | Child-Pugh A or B: No specific adjustment; Child-Pugh C: Use with caution, reduce initial dose and titrate slowly based on response and tolerability. |
| Pediatric use | Not FDA-approved for pediatric use. Limited data: Octreotide for secretory diarrhea: 1-2 mcg/kg subcutaneously initially, then titrate to 5-10 mcg/kg daily in divided doses. For variceal bleeding: 25-50 mcg/m2/hour continuous IV; maximum 75 mcg/m2/hour. |
| Geriatric use | No specific dose adjustment recommended; consider increased sensitivity to adverse effects (bradycardia, electrolyte disturbances). Start at low end of dosing range and titrate cautiously. Renal function may be reduced, monitor closely. |
| 1st trimester | Octreotide acetate use during the first trimester is not recommended unless clearly necessary. Animal studies have shown no teratogenic effects but there are no adequate human studies. |
| 2nd trimester | Use in the second trimester only if potential benefit justifies potential risk to the fetus. Limited human data; consider dose adjustment and monitoring. |
| 3rd trimester | Use during third trimester may cause fetal adverse effects (e.g., growth restriction) due to inhibition of growth hormone. Monitor fetal growth if used. |
Clinical note
Comprehensive clinical and safety monograph for OCTREOTIDE ACETATE (OCTREOTIDE ACETATE).
| Placental transfer | Octreotide crosses the placenta in animals; human data are limited but transfer is expected due to its molecular weight and structure. |
| Breastfeeding | Octreotide is excreted into human milk in low amounts. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
Hypersensitivity to octreotide or any component of the formulation
| Precautions | Cholelithiasis: increased risk due to inhibition of gallbladder motility and bile secretion, Glucose metabolism disturbances: hyper- or hypoglycemia, Cardiovascular effects: bradycardia, conduction abnormalities, Hypothyroidism: may suppress TSH secretion, Gallbladder sludge or stones, Vitamin B12 deficiency with long-term use |
| Food/Dietary | Octreotide has no known specific food interactions. However, since it slows GI motility and reduces insulin release, patients with diabetes should maintain consistent carbohydrate intake to avoid blood glucose fluctuations. Avoid high-fat meals to minimize GI discomfort and potential exacerbation of gallbladder symptoms. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Octreotide acetate is not recommended during pregnancy, especially in the first trimester, due to limited human data. Animal studies have shown no evidence of teratogenicity at clinically relevant doses. Use only if clearly needed. |
| Fetal Monitoring | Monitor maternal blood glucose levels, thyroid function, and gallbladder ultrasound. Fetal growth ultrasound if used long-term. Assess for signs of hypoglycemia or hyperglycemia. |
| Fertility Effects | Octreotide may inhibit growth hormone and affect menstrual cycle, potentially impacting fertility. Reversibility upon discontinuation is expected. |
| Clinical Pearls | Octreotide is a somatostatin analog used for acromegaly, carcinoid syndrome, and VIPomas. Administer via subcutaneous or intravenous routes; depot formulations (octreotide LAR) require deep gluteal injection. Monitor for gallbladder sludge/stones due to inhibition of gallbladder contraction. Can cause bradycardia and conduction abnormalities; obtain baseline ECG and monitor electrolytes. Adjust dose in hepatic impairment. May reduce efficacy of cyclosporine and alter insulin requirements. |
| Patient Advice | Take octreotide exactly as prescribed; do not stop without consulting your doctor. · For injectable solution, rotate injection sites and use sterile technique. · Report symptoms of gallstones: right upper abdominal pain, nausea, vomiting, fever. · Monitor blood sugar regularly if diabetic; octreotide can cause hyperglycemia or hypoglycemia. · Avoid alcohol and high-fat meals that may worsen GI side effects. · Carry medical ID if using for carcinoid syndrome or other chronic condition. · Contact your doctor if you experience slow heart rate, dizziness, or fainting. |